Product image of Novantron (Mitoxantrone) supplied by GNH India

Novantron

Active Ingredient:
Mitoxantrone
Origin:
EU

Novantron (Mitoxantrone)

Mitoxantrone, the active ingredient in Novantron, is an anthracenedione presented as an intravenous formulation for infusion use. It is employed in the treatment of certain hematologic malignancies and solid tumors in adult patients.

GNH India supplies Novantron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to European Union quality standards and provides regulatory documentation for importers. Novantron is manufactured under GMP conditions and distributed through a temperature‑controlled logistics network to ensure product integrity.

Manufacturer / TM Owner

Viatris Healthcare Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Novantron (mitoxantrone) is used in the management of malignant diseases that involve rapidly dividing cells.

  • Acute myeloid leukemia: improves remission rates and prolongs survival in adult patients.
  • Prostate cancer: provides disease control in hormone‑refractory cases.
  • Breast cancer: used in metastatic disease to achieve tumor reduction.
  • Non‑Hodgkin lymphoma: contributes to response in relapsed or refractory disease.

How It Works

  • Mitoxantrone intercalates between DNA base pairs and inhibits topoisomerase II, preventing the re‑ligation of DNA strands during replication. This action generates double‑strand breaks, disrupts transcription, and induces apoptosis of rapidly proliferating cancer cells. The drug also produces free radicals that further damage cellular components, enhancing its cytotoxic effect.

Side Effects

Novantron may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Fatigue: persistent tiredness affecting daily activities.
  • Alopecia: reversible hair loss during treatment.
  • Myelosuppression: reduced white blood cells, red cells, and platelets.

Serious or Rare Side Effects

  • Cardiotoxicity: decreased left‑ventricular ejection fraction, potentially irreversible.
  • Secondary leukemia: emergence of a new hematologic malignancy.
  • Severe infection: opportunistic infections due to profound neutropenia.
  • Pulmonary toxicity: interstitial pneumonitis or fibrosis.

Precautions & Warnings

When using Novantron, clinicians should observe several safety measures to minimize risks.

  • Cardiac monitoring: baseline and periodic ejection‑fraction assessments are recommended.
  • Hematologic surveillance: regular complete blood counts to detect myelosuppression.
  • Liver function: periodic liver‑enzyme testing for hepatic toxicity.
  • Contraindication in severe cardiac disease: avoid in patients with pre‑existing heart failure.
  • Pregnancy and lactation: avoid unless benefits outweigh potential fetal or neonatal risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Novantron can interact with several agents, requiring careful management.

Major Interactions (Avoid)

  • Concurrent anthracyclines: additive cardiotoxicity may be life‑threatening.
  • Live vaccines: immunosuppression can lead to uncontrolled infection.
  • High‑dose radiotherapy: increased risk of tissue damage.

Moderate Interactions (Monitor Closely)

  • Anticoagulants: heightened bleeding risk due to thrombocytopenia.
  • CYP3A4 inhibitors: may increase mitoxantrone plasma concentrations.
  • Granulocyte‑colony stimulating factors: may mask severity of myelosuppression.

Frequently Asked Questions

Novantron is the brand name for the chemotherapy agent mitoxantrone. It is indicated for the treatment of acute myeloid leukemia, hormone‑refractory prostate cancer, metastatic breast cancer, and relapsed or refractory non‑Hodgkin lymphoma in adult patients.

Mitoxantrone intercalates into DNA and blocks the activity of topoisomerase II, an enzyme required for DNA replication. This inhibition creates double‑strand breaks, disrupts transcription, and triggers apoptosis of rapidly dividing cancer cells.

The dosing regimen for Novantron is individualized by the treating oncologist based on the specific cancer type, disease stage, patient weight, renal function, and prior therapies. Only a qualified prescriber can determine the appropriate dose and schedule.

Safety data for mitoxantrone in pregnancy and lactation are limited. The drug is generally avoided during pregnancy and breastfeeding because of potential fetal toxicity and excretion in breast milk. Use only if the potential benefit justifies the risk.

To request Novantron, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Novantron belongs to the anthracenedione class, which is chemically related to anthracyclines such as doxorubicin. Compared with anthracyclines, mitoxantrone has a lower incidence of acute cardiotoxicity at equivalent doses but still requires cardiac monitoring. Both classes share myelosuppression as a common toxicity.

Novantron must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until preparation, and handling should follow aseptic techniques to maintain sterility.

Novantron is supplied as an injectable solution for intravenous infusion. It is administered by a qualified healthcare professional, typically over a period of 30‑60 minutes, depending on the prescribed dose and patient tolerance.

The most serious adverse events include cardiotoxicity (reduced left‑ventricular function), secondary acute leukemia, severe myelosuppression leading to infection or bleeding, and pulmonary toxicity. Patients should be monitored regularly for cardiac function, blood counts and respiratory symptoms.

Novantron is contraindicated in patients with pre‑existing severe cardiac disease, uncontrolled infections, or known hypersensitivity to mitoxantrone or any formulation component. It should also be avoided in pregnant women unless the therapeutic benefit outweighs the potential fetal risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mitoxantrone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT